Fuji Pharma Co., Ltd. (4554.T)
JPY 1361.0
(0.29%)
JPY 1361.0
(0.29%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 3.43 Billion JPY | 27.41% |
| 2022 | 2.69 Billion JPY | 10.86% |
| 2021 | 2.43 Billion JPY | 16.64% |
| 2020 | 2.08 Billion JPY | -29.61% |
| 2019 | 2.96 Billion JPY | -12.16% |
| 2018 | 3.37 Billion JPY | 2.15% |
| 2017 | 3.3 Billion JPY | 55.85% |
| 2016 | 2.11 Billion JPY | 1.24% |
| 2015 | 2.09 Billion JPY | 0.67% |
| 2014 | 2.07 Billion JPY | 0.48% |
| 2013 | 2.06 Billion JPY | 50.85% |
| 2012 | 1.37 Billion JPY | -37.82% |
| 2011 | 2.2 Billion JPY | 13.41% |
| 2010 | 1.94 Billion JPY | 27.4% |
| 2009 | 1.52 Billion JPY | 21.91% |
| 2008 | 1.25 Billion JPY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 1.51 Billion JPY | -44.58% |
| 2024 Q1 | 2.73 Billion JPY | 88.51% |
| 2024 Q3 | 653 Million JPY | -56.98% |
| 2023 Q3 | 210 Million JPY | -68.09% |
| 2023 Q4 | 1.45 Billion JPY | 591.9% |
| 2023 FY | 3.43 Billion JPY | 27.41% |
| 2023 Q1 | 1.11 Billion JPY | 1962.96% |
| 2023 Q2 | 658 Million JPY | -40.93% |
| 2022 Q2 | 716 Million JPY | -35.96% |
| 2022 Q1 | 1.11 Billion JPY | 634.93% |
| 2022 FY | 2.69 Billion JPY | 10.86% |
| 2022 Q4 | 54 Million JPY | -93.32% |
| 2022 Q3 | 808 Million JPY | 12.85% |
| 2021 Q2 | 693 Million JPY | -47.82% |
| 2021 FY | 2.43 Billion JPY | 16.64% |
| 2021 Q1 | 1.32 Billion JPY | 155.38% |
| 2021 Q3 | 620 Million JPY | -10.53% |
| 2021 Q4 | -209 Million JPY | -133.71% |
| 2020 Q1 | 745 Million JPY | 68.93% |
| 2020 FY | 2.08 Billion JPY | -29.61% |
| 2020 Q2 | -435 Million JPY | -158.39% |
| 2020 Q3 | 1.25 Billion JPY | 388.51% |
| 2020 Q4 | 520 Million JPY | -58.57% |
| 2019 Q4 | 441 Million JPY | -46.61% |
| 2019 FY | 2.96 Billion JPY | -12.16% |
| 2019 Q1 | 1.09 Billion JPY | 43.08% |
| 2019 Q2 | 599 Million JPY | -45.35% |
| 2019 Q3 | 826 Million JPY | 37.9% |
| 2018 Q2 | 442 Million JPY | -66.03% |
| 2018 Q1 | 1.3 Billion JPY | 112.23% |
| 2018 Q3 | 863 Million JPY | 95.25% |
| 2018 Q4 | 766 Million JPY | -11.24% |
| 2018 FY | 3.37 Billion JPY | 2.15% |
| 2017 FY | 3.3 Billion JPY | 55.85% |
| 2017 Q3 | 899 Million JPY | 26.26% |
| 2017 Q2 | 712 Million JPY | -33.89% |
| 2017 Q1 | 1.07 Billion JPY | 137.75% |
| 2017 Q4 | 613 Million JPY | -31.81% |
| 2016 Q4 | 453 Million JPY | -23.61% |
| 2016 FY | 2.11 Billion JPY | 1.24% |
| 2016 Q1 | 545 Million JPY | -20.9% |
| 2016 Q2 | 527 Million JPY | -3.3% |
| 2016 Q3 | 593 Million JPY | 12.52% |
| 2015 Q3 | 532 Million JPY | 49.86% |
| 2015 FY | 2.09 Billion JPY | 0.67% |
| 2015 Q1 | 516 Million JPY | -17.7% |
| 2015 Q2 | 355 Million JPY | -31.2% |
| 2015 Q4 | 689 Million JPY | 29.51% |
| 2014 FY | 2.07 Billion JPY | 0.48% |
| 2014 Q4 | 627 Million JPY | 39.64% |
| 2014 Q3 | 449 Million JPY | -2.18% |
| 2014 Q2 | 459 Million JPY | -15.47% |
| 2014 Q1 | 543 Million JPY | -15.55% |
| 2013 Q4 | 643 Million JPY | 90.8% |
| 2013 Q3 | 337 Million JPY | -29.2% |
| 2013 FY | 2.06 Billion JPY | 50.85% |
| 2013 Q2 | 476 Million JPY | -22.22% |
| 2013 Q1 | 612 Million JPY | 5.85% |
| 2012 Q1 | -17.89 Million JPY | -102.97% |
| 2012 Q4 | 578.2 Million JPY | 20.65% |
| 2012 Q3 | 479.23 Million JPY | 44.61% |
| 2012 FY | 1.37 Billion JPY | -37.82% |
| 2012 Q2 | 331.38 Million JPY | 1952.15% |
| 2011 Q4 | 601.68 Million JPY | 6.83% |
| 2011 Q1 | 561.96 Million JPY | 22.68% |
| 2011 FY | 2.2 Billion JPY | 13.41% |
| 2011 Q3 | 563.23 Million JPY | 17.84% |
| 2011 Q2 | 477.96 Million JPY | -14.95% |
| 2010 Q4 | 458.08 Million JPY | -11.03% |
| 2010 Q2 | 400.58 Million JPY | -29.79% |
| 2010 Q3 | 514.87 Million JPY | 28.53% |
| 2010 Q1 | 570.52 Million JPY | -5.55% |
| 2010 FY | 1.94 Billion JPY | 27.4% |
| 2009 Q1 | 285.55 Million JPY | 0.0% |
| 2009 Q2 | 261.52 Million JPY | -8.41% |
| 2009 Q3 | 374.8 Million JPY | 43.32% |
| 2009 Q4 | 604.07 Million JPY | 61.17% |
| 2009 FY | 1.52 Billion JPY | 21.91% |
| 2008 FY | 1.25 Billion JPY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 3.2 Billion JPY | -7.176% |
| Takeda Pharmaceutical Company Limited | 144.06 Billion JPY | 97.616% |
| Sumitomo Pharma Co., Ltd. | -314.96 Billion JPY | 101.091% |
| Shionogi & Co., Ltd. | 162.03 Billion JPY | 97.88% |
| Wakamoto Pharmaceutical Co.,Ltd. | 108.95 Million JPY | -3052.562% |
| Nippon Shinyaku Co., Ltd. | 25.85 Billion JPY | 86.712% |
| Kaken Pharmaceutical Co., Ltd. | 8.02 Billion JPY | 57.196% |
| Eisai Co., Ltd. | 42.4 Billion JPY | 91.9% |
| Morishita Jintan Co., Ltd. | 697 Million JPY | -392.826% |
| Hisamitsu Pharmaceutical Co., Inc. | 13.96 Billion JPY | 75.41% |
| Mochida Pharmaceutical Co., Ltd. | 4.54 Billion JPY | 24.456% |
| Fuso Pharmaceutical Industries,Ltd. | 1.37 Billion JPY | -149.455% |
| Nippon Chemiphar Co., Ltd. | -180 Million JPY | 2008.333% |
| Tsumura & Co. | 16.7 Billion JPY | 79.44% |
| Kissei Pharmaceutical Co., Ltd. | 11.16 Billion JPY | 69.22% |
| Torii Pharmaceutical Co., Ltd. | 4.11 Billion JPY | 16.606% |
| Towa Pharmaceutical Co., Ltd. | 16.17 Billion JPY | 78.761% |
| Zeria Pharmaceutical Co., Ltd. | 7.73 Billion JPY | 55.57% |
| KYORIN Holdings, Inc. | 5.32 Billion JPY | 35.457% |
| Taiko Pharmaceutical Co.,Ltd. | -4.89 Billion JPY | 170.188% |
| Daito Pharmaceutical Co.,Ltd. | 3.29 Billion JPY | -4.249% |
| SymBio Pharmaceuticals Limited | -1.96 Billion JPY | 275.004% |
| MedRx Co., Ltd | -932 Million JPY | 468.562% |
| Mizuho Medy Co.,Ltd. | 3.77 Billion JPY | 8.988% |
| Solasia Pharma K.K. | -1.11 Billion JPY | 408.903% |
| Modalis Therapeutics Corporation | -2.39 Billion JPY | 243.614% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 7.54 Billion JPY | 54.473% |
| Sawai Group Holdings Co., Ltd. | 13.69 Billion JPY | 74.918% |
| Cyfuse Biomedical K.K. | -589.21 Million JPY | 682.983% |
| Toho Holdings Co., Ltd. | 20.65 Billion JPY | 83.371% |
| Koa Shoji Holdings Co.,Ltd. | 2.94 Billion JPY | -16.585% |